Eosinophil Progenitors in Patients With Non-Asthmatic Eosinophilic Bronchitis, Eosinophilic Asthma, and Normal Controls.
Eosinophil Progenitors in Patients With Non-Asthmatic Eosinophilic Bronchitis, Eosinophilic Asthma, and Normal Controls.
复制标题
非哮喘性嗜酸性支气管炎、嗜酸性哮喘和正常对照患者的嗜酸性粒细胞祖细胞
DOI：
10.3389/fimmu.2022.737968
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
本研究旨在探讨非哮喘性嗜酸性支气管炎（NAEB）、嗜酸性哮喘（EA）和健康对照（HC）患者痰液和外周血中嗜酸性祖细胞（EoPs）和造血祖细胞（HPCs）气道原位分化的潜力。使用流式细胞术，我们在基线时对NAEB （n=15）、EA （n=15）和HC （n=14）患者的痰液和血液HPCs和EoPs进行了计数。NAEB和EA患者分别给予布地奈德（200 μg, bid）或布地奈德加福莫特罗（200/6 μg, bid）治疗1个月。重新评估两室的HPCs和EoPs。在基线时，NAEB和EA的痰中HPCs和EoPs数量均显著高于HC，而血中HPCs和EoPs数量无显著差异（p<0.05）。NAEB与EA无明显差异。吸入皮质类固醇（ICS）治疗1个月后，NAEB患者咳嗽症状有明显改善，但痰HPC和EoP水平的降低不显著。NAEB患者气道HPCs和EoPs水平升高。1个月的ICS治疗不能完全抑制NAEB的EoPs水平。控制EoPs的原位气道分化可能控制气道嗜酸性粒细胞增多，并提供NAEB症状的长期解决方案。
This study aims to explore the potential of in situ airway differentiation of eosinophil progenitors (EoPs) and hematopoietic progenitor cells (HPCs) in sputum and peripheral blood from patients with non-asthmatic eosinophilic bronchitis (NAEB), eosinophilic asthma (EA), and healthy controls (HC). Using flow cytometry, we enumerated sputum and blood HPCs and EoPs in patients with NAEB (n=15), EA (n=15), and HC (n=14) at baseline. Patients with NAEB and EA were then treated for 1 month with budesonide (200 μg, bid) or budesonide and formoterol (200/6 μg, bid), respectively. HPCs and EoPs in both compartments were re-evaluated. At baseline, NAEB and EA both had significantly greater numbers of sputum but not blood HPCs and EoPs (p<0.05) compared to HC. There were no differences between NAEB and EA. After 1 month of inhaled corticosteroid (ICS) treatment, NAEB patients showed a significant improvement in cough symptoms, but the attenuation of sputum HPC and EoP levels was not significant. NAEB patients have increased airway levels of HPCs and EoPs. One-month treatment with ICS did not fully suppress the level of EoPs in NAEB. Controlling in situ airway differentiation of EoPs may control airway eosinophilia and provide long-term resolution of symptoms in NAEB.